Articles related to PATIENT CARE

U.S. News expanded its 2026-2027 hospital rankings with new regional specialty evaluations in cancer and cardiovascular care while increasing recognition for regional hospitals. Rankings continued to emphasize risk-adjusted mortality, preventable complications, patient experience, and objective outcomes measures.

The FDA approved Furoscix ReadyFlow, a subcutaneous furosemide autoinjector for edema associated with heart failure or chronic kidney disease. Clinical data demonstrated pharmacokinetic exposure and diuretic effects comparable to intravenous furosemide.

ASCO released updated recommendations for recurrent ovarian cancer that reinforce platinum-based doublet therapy as the preferred approach for platinum-sensitive disease and provide guidance for platinum-resistant disease, maintenance strategies, and monitoring. Recommendations were derived from a systematic review of studies published through 2025.

An 8-week observational study of young adults with acne found significant improvements in both acne severity and dermatology-related quality of life. Improvements in clinical grading did not correlate with patient-reported quality-of-life gains, highlighting the multidimensional impact of acne.

Accumulating evidence suggests that initiating effective therapy earlier in Crohn’s disease may reduce bowel damage progression, hospitalizations, and surgery. Long-term follow-up from recent studies has strengthened interest in a therapeutic window during which disease modification may be achievable.

The Main Street Pharmacy Access Act (H.R. 3164/S. 2426), which would authorize Medicare reimbursement for pharmacist-provided testing and treatment of flu, strep, RSV, and COVID-19 in states that already permit those services, cleared the House Committee on Ways and Means on May 21 with more than 110 congressional co-sponsors and support from over 170 organizations.